Belimumab in Active lupus nephritis , Ken Kalunian #RNL2023 ⁦@RheumNow⁩ https://t.co/VZkmK8Iny7

Carpal Tunnel - Steroid injection vs. Night Splinting A randomized trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSIor NS as the initial treatment of CTS. https://t.co/dcE2P6RqoC https://t.co/pykkXs8qqi

• https://bit.ly/3YXAQ6s

Risk of adverse outcomes in PsA pregnancies More pre eclampsia More Cesarian section More preterms By Dr.Chambers #RNL2023 ⁦@RheumNow⁩ https://t.co/LRiSSpv4Yj

Smoking *may* only ⬆️ risk of #RA if shared epitope present AND double positive By @Janetbirdope #RNL2023 https://t.co/TG1hseVCsD

#RNL2023 Year in Review @andreafava: urinary biomarkers in lupus nephritis CD163, IL-16, CD206 decrease at 3 months. Urinary biomarkers predict 1 year proteinuric response, esp in prolif LN. Liquid biopsy as way to monitor instead of serial biopsies @RheumNow https://t.co/baZt57Qjne

Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment @RheumNow #RNL2023 https://t.co/kNDouZ4kCV

#RNL2023 Year in Review HCQ levels in SLE >500 ng/mL = 19x higher adherence >750 ng/mL 67% lower odds of adherence Higher levels with CKD I use HCQ levels in all patients for monitoring at each visit @RheumNow https://t.co/6yCefQdPU0

#RNL2023 Year in Review COMPLETE-PsA: DMARDs for PsA! LEF+MTX better than MTX alone, 78 total patients PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO More treatment discontinuations (10 vs 3) in combo group due to GI intolerance @RheumNow https://t.co/3Al8PQmNli

PMR classification criteria by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Bursal and biceps tenosynovitis gets one point in PMR classification criteria. https://t.co/Lj1X9mkgBz

Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow

#RNL2023 Year in Review Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA. More targeted studies needed @RheumNow https://t.co/Z3kbM0e9A0

Should we be measuring HCQ levels? - note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels - adjust dose for pts with renal impairment @RheumNow #RNL2023 https://t.co/JvaRJKJRPv

#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow https://t.co/bW00Wg6Cnf

Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49

Could MTX every other week dosing be an option in patients with stable disease..? #RNL2023 https://t.co/EZRdQnuXjy